Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,363 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,720 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,404)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | recruiting | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05642338 | A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study(WATSEURO2) | recruiting | — | 416 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| 1 |
| Dec 8, 2022 |
| clinicaltrials |
| NCT05331911 | Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors | recruiting | Phase 4 | 500 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05356039 | Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer(SQUARE) | recruiting | — | 300 | Umeå UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT04720339 | Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. | recruiting | N/A | 250 | University Hospital, Strasbourg, FranceOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05620706 | Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05620732 | Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T | recruiting | N/A | 20 | Shenzhen University General HospitalOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT05611515 | Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies(SUPRA-QoL) | recruiting | — | 108 | Centre Hospitalier Universitaire UCLouvain NamurOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT04078230 | Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma | recruiting | N/A | 168 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 2 | Nov 9, 2022 | clinicaltrials |
| NCT05608213 | Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC | recruiting | Phase 3 | 187 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03280511 | Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients | recruiting | Phase 2 | 60 | Michael Bau MortensenOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03747588 | The Comparision of Minimally-invasive and Open Pancreaticoduodenectomy for Pancreatic Cancer(MIOPP) | recruiting | N/A | 100 | Peking Union Medical College HospitalOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04673955 | BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment(BERING-CRC) | recruiting | — | 500 | Pierre Fabre Pharma GmbHINDUSTRY | 2 | Sep 29, 2022 | clinicaltrials |
| NCT05541601 | Prospective Cohort for Early Detection of Liver Cancer(Pearl) | recruiting | — | 3,000 | University of OxfordOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05534906 | The Detection of Small Early Liver Cancer With Natural History Follow up(SELINA) | recruiting | — | 250 | University of OxfordOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05339568 | Patient's Whole Process Follow-up Management(HOPE-1)(HOPE-1) | recruiting | — | 1,268 | Qianfoshan HospitalOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05276037 | Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates | recruiting | — | 350 | University of LiegeOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524090 | PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer(PREOPANC-4) | recruiting | — | 223 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05334277 | Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA(FOCUS-C) | recruiting | Phase 2 | 280 | Sun Yat-sen UniversityOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT04875585 | Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC(INNWOP1) | recruiting | Phase 2 | 33 | Medical University InnsbruckOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05514275 | Radiotherapy Combined With Endostatin and Capecitabine for NPC | recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT04108936 | Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses(CRS/HIPEC) | recruiting | — | 250 | University of RegensburgOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05507411 | Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC(WATCHER) | recruiting | Phase 2 | 100 | Zhejiang Cancer HospitalOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05503667 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | recruiting | Phase 2 | 96 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04926584 | Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option(KOMPASSneo) | recruiting | — | 50 | Klinikum EsslingenOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05498064 | A Real World Study of Ensartinib in Advanced ALK-positive NSCLC | recruiting | — | 490 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05397769 | Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04138212 | Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)(HCHTOG1903) | recruiting | Phase 3 | 456 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 9, 2022 | clinicaltrials |
| NCT04985032 | Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) | recruiting | — | 200 | RPCR, Inc.OTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04681469 | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC(PRIME) | recruiting | Phase 2 | 49 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05366478 | A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 15 | Suzhou BlueHorse Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05469022 | Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy | recruiting | Phase 2 | 40 | Konkuk University Medical CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05466565 | Antiviral Therapy for Patients With Liver Cancer After Surgery | recruiting | — | 360 | Xiangya Hospital of Central South UniversityOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05447169 | Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening | recruiting | — | 11,625 | Sun Yat-sen UniversityOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05392413 | Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody | recruiting | — | 200 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05352321 | Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma | recruiting | N/A | 264 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04973306 | Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC(iCROSS) | recruiting | Phase 2 / Phase 3 | 176 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 16, 2022 | clinicaltrials |
| NCT04499833 | HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma(HepatoPredict) | recruiting | N/A | 40 | Centro Hospitalar de Lisboa CentralOTHER | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04306458 | RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).(ROBOT-2) | recruiting | N/A | 218 | University Medical Center MainzOTHER | 1 | May 17, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05037825 | The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors(PARADIGM) | recruiting | — | 800 | VastBiomeINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05345860 | Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer(AMENDER) | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT02354274 | Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine® | recruiting | N/A | 330 | Olfred HansenOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2022source: clinicaltrials